Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: May 21, 2025 · CIK: 2022416
Sentiment: neutral
Topics: 8-K, reporting, financials
Related Tickers: SLXN
TL;DR
Silexion Therapeutics filed a routine 8-K on 5/21/25. No major news.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 21, 2025, reporting on financial statements and exhibits. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and trades on NASDAQ under the ticker SLXN. This filing does not appear to contain specific financial transaction details or material events beyond routine reporting.
Why It Matters
This 8-K filing indicates routine corporate reporting by Silexion Therapeutics Corp. to the SEC, providing transparency for investors regarding their financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- May 21, 2025 (date) — Date of report
- NASDAQ (company) — Exchange traded on
- SLXN (ticker) — Ticker symbol
FAQ
What is the primary purpose of this 8-K filing for Silexion Therapeutics Corp?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of May 21, 2025.
When was Silexion Therapeutics Corp. previously known by another name?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, with a date of name change on May 6, 2024.
Where is Silexion Therapeutics Corp. headquartered?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
On which stock exchange does Silexion Therapeutics Corp. trade?
Silexion Therapeutics Corp. trades on NASDAQ.
What is the Commission File Number for Silexion Therapeutics Corp.?
The Commission File Number for Silexion Therapeutics Corp. is 001-42253.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding Silexion Therapeutics Corp (SLXNW).